

**LEARNING OBJECTIVE:** Readers will apply current guidelines and evidence to the care of their perioperative patients

**RYAN MUNYON, MD**

Assistant Professor of Medicine, Penn State University; Director, Consult and Co-management Services, General Internal Medicine, Penn State Hershey Medical Center, Hershey, PA

**STEVEN L. COHN, MD, FACP, SFHM**

Professor Emeritus, University of Miami Miller School of Medicine; Director, Medical Consultation Service, Jackson Memorial Hospital, Miami, FL

**BARBARA SLAWSKI, MD, MS, SFHM**

Professor of Medicine and Orthopedic Surgery; Chief, Section of Perioperative and Consultative Medicine; Division of General Internal Medicine; Department of Medicine, Medical College of Wisconsin, Milwaukee

**GERALD W. SMETANA, MD, MACP**

Professor of Medicine, Harvard Medical School; Division of General Medicine and Primary Care, Beth Israel Deaconess Medical Center, Boston, MA

**KURT PFEIFER, MD, FACP, SFHM**

Professor of Medicine, General Internal Medicine, Medical College of Wisconsin, Milwaukee

# 2017 Update in perioperative medicine: 6 questions answered

## ABSTRACT

The authors performed a MEDLINE search to identify articles published between January 2016 and April 2017 that had significant impact on perioperative care. They identified 6 topics for discussion.

## KEY POINTS

Noncardiac surgery after drug-eluting stent placement can be considered after 3 to 6 months for those with greater surgical need and lower risk of stent thrombosis.

Perioperative statin use continues to show benefits with minimal risk in large cohort studies, but significant randomized controlled trial data are lacking.

Patients should be screened for obstructive sleep apnea before surgery, and further cardiopulmonary testing should be performed if the patient has evidence of significant sequelae from obstructive sleep apnea.

For patients with atrial fibrillation on vitamin K antagonists, bridging can be considered for those with a CHA<sub>2</sub>DS<sub>2</sub>-VASc score of 5 or 6 and a history of stroke, transient ischemic attack, or systemic thromboembolism. Direct oral anticoagulation should not be bridged.

Frailty carries significant perioperative mortality risk; systems-based changes to minimize these patients' risks can be beneficial and warrant further study.

PERIOPERATIVE CARE is increasingly complex, and the rapid evolution of literature in this field makes it a challenge for clinicians to stay up-to-date. To help meet this challenge, we used a systematic approach to identify appropriate articles in the medical literature and then, by consensus, to develop a list of 6 clinical questions based on their novelty and potential to change perioperative medical practice:

- How should we screen for cardiac risk in patients undergoing noncardiac surgery?
- What is the appropriate timing for surgery after coronary intervention?
- Can we use statin therapy to reduce perioperative cardiac risk?
- How should we manage sleep apnea risk perioperatively?
- Which patients with atrial fibrillation should receive perioperative bridging anticoagulation?
- Is frailty screening beneficial for elderly patients before noncardiac surgery?

The summaries in this article are a composite of perioperative medicine updates presented at the Perioperative Medicine Summit and the annual meetings of the Society for General Internal Medicine and the Society of Hospital Medicine. "Perioperative care is complex and changing"<sup>1-10</sup> (page 864) offers a brief overview.

## ■ HOW TO SCREEN FOR CARDIAC RISK BEFORE NONCARDIAC SURGERY

Perioperative cardiac risk can be estimated by clinical risk indexes (based on history, physical examination, common blood tests, and electrocardiography), cardiac biomarkers (natriuretic peptide or troponin levels), and non-invasive cardiac tests.

## Perioperative care is complex and changing

The care of perioperative patients is increasingly complex, and information is rapidly changing.

**Risk assessment.** The new Canadian Cardiovascular Society guidelines on perioperative risk assessment and management<sup>1</sup> differ significantly from those of the American College of Cardiology/American Heart Association<sup>2</sup> regarding the use of risk-assessment tools and biomarkers before surgery. Further study is required to determine if outcomes improve with biomarker use in perioperative cardiac risk stratification.

**Surgery after PCI.** The 2016 American College of Cardiology/American Heart Association guideline on dual antiplatelet therapy in patients with coronary artery disease incorporated newer data with newer stent devices and recommended a reduced time needed for delay of noncardiac surgery.<sup>3</sup> For patients with greater need for surgery and lower risk of stent thrombosis, noncardiac surgery can be considered 3 to 6 months after stent placement.

**Statins.** Large cohort studies show that perioperative statin use has significant benefit and low risk.<sup>4,5</sup> Unfortunately, a recent randomized controlled trial could not show a significant benefit for perioperative initiation of statins.<sup>6</sup>

**Obstructive sleep apnea.** Undiagnosed obstructive sleep apnea is common and carries significant perioperative risk. Patients should be screened for it before surgery with a validated screening tool, pertinent history, and physical examination. Patients who are determined to be at high risk for obstructive sleep apnea should have joint decision-making with the

surgical teams regarding proceeding with surgery with empiric continuous positive airway pressure or delaying it for a formal sleep study. Furthermore, the Society of Anesthesia and Sleep Medicine recommends cardiopulmonary evaluation if there is evidence of hypoventilation, hypoxemia, or pulmonary hypertension in addition to likely obstructive sleep apnea.<sup>7</sup>

**Bridging anticoagulation.** The 2017 American College of Cardiology guidelines for periprocedural anticoagulation for patients with atrial fibrillation recommend risk stratification with the CHA<sub>2</sub>DS<sub>2</sub>-VASc score.<sup>8</sup> They further recommend balancing the procedural bleeding risk with the thromboembolic risk, but of note, periprocedural bridging can now be considered for patients with a CHA<sub>2</sub>DS<sub>2</sub>-VASc score of 5 or 6 on vitamin K antagonists and a history of stroke, transient ischemic attack, or systemic thromboembolism. Direct oral anticoagulation does not require bridging.

**Frailty.** A recent large study by McIsaac et al<sup>9</sup> demonstrated that frail patients had a significantly increased 1-year postoperative mortality rate. Further research is needed to determine the best way to minimize risk for frail patients, but Hall et al<sup>10</sup> demonstrated a significant improvement in perioperative mortality using a systematic quality-improvement process that involves identifying frail patients and performing higher-vigilance, individualized perioperative planning.

Frailty is a multifaceted, heterogeneous diagnosis. As a whole, it carries significant perioperative risk and warrants further study into identification and comprehensive risk-minimization.

### American and European guidelines

In 2014, the American College of Cardiology/American Heart Association<sup>2</sup> and the European Society of Cardiology<sup>11</sup> published guidelines on perioperative cardiovascular evaluation and management. They recommended several tools to calculate the risk of postoperative cardiac complications but did not specify a preference. These tools include:

- The Revised Cardiac Risk Index (RCRI)<sup>12</sup> ([www.mdcalc.com/revised-cardiac-risk-index-pre-operative-risk](http://www.mdcalc.com/revised-cardiac-risk-index-pre-operative-risk)), which has been externally validated in multiple studies and is the most widely used
- The American College of Surgeons surgical risk calculator<sup>13</sup> ([www.riskcalculator.facs.org](http://www.riskcalculator.facs.org)), derived from the National Surgery Quality Improvement Program (NSQIP) database
- The myocardial infarction or cardiac ar-

rest (MICA) calculator<sup>14</sup> ([www.surgical-riskcalculator.com/miocardiacarrest](http://www.surgical-riskcalculator.com/miocardiacarrest)), also derived from the NSQIP database.


### 2017 Canadian guidelines differ

In 2017, the Canadian Cardiovascular Society published its own guidelines on perioperative risk assessment and management.<sup>1</sup> These differ from the American and European guidelines on several points.

**RCRI recommended.** The Canadian guidelines suggested using the RCRI over the other risk predictors, which despite superior discrimination lacked external validation (conditional recommendation; low-quality evidence). Additionally, the Canadians believed that the NSQIP risk indexes underestimated cardiac risk because patients did not undergo routine biomarker screening.

**Biomarker measurement.** The Canadian guidelines went a step further in their algo-

Patients ages 45 and older, or ages 18–44 with known significant cardiovascular disease<sup>a</sup> undergoing noncardiac surgery that requires overnight hospital admission



<sup>a</sup> Significant cardiovascular disease includes known history of coronary artery disease, cerebral vascular disease, peripheral artery disease, congestive heart failure, severe pulmonary hypertension, or a severe obstructive intracardiac abnormality (eg, severe aortic stenosis, severe mitral stenosis, severe hypertrophic obstructive cardiomyopathy).

<sup>b</sup> If physical examination suggests there is an unknown severe obstructive intracardiac abnormality (eg, severe aortic stenosis, severe mitral stenosis, severe hypertrophic obstructive cardiomyopathy) or severe pulmonary hypertension, then obtain an echocardiogram before surgery to inform the anesthesiologist, surgeon, and medical team of the type and degree of disease. If the history suggests an unstable cardiac condition (eg, unstable angina), then discussion with the patient and surgical-medical team is required to decide whether to delay, cancel, or proceed with surgery.

<sup>c</sup> RCRI score (each worth 1 point): history of coronary artery disease, cerebrovascular disease, congestive heart failure, preoperative insulin use, preoperative creatinine > 177 μmol/L (2.0 mg/dL), and high-risk surgery (ie, intraperitoneal, intrathoracic, or suprainguinal vascular surgery).

<sup>d</sup> Shared-care management refers to a multidisciplinary approach to inpatient postoperative care; this includes the surgeon and a medical specialist (eg, internist, cardiologist, gerontologist), who will help with perioperative monitoring and management of cardiovascular complications.

NT-proBNP = N-terminal-pro B-type natriuretic peptide

## FIGURE 1. Canadian guidelines on preoperative risk assessment and postoperative monitoring.

Reprinted from Duceppe E, Parlow J, MacDonald P, et al. Canadian Cardiovascular Society guidelines on perioperative cardiac risk assessment and management for patients who undergo noncardiac surgery. *Can J Cardiol* 2017; 33:17–32, with permission from Elsevier, [www.sciencedirect.com/science/journal/0828282X?sdsc=1](http://www.sciencedirect.com/science/journal/0828282X?sdsc=1).

rhythm (Figure 1) and recommended measuring N-terminal-pro B-type natriuretic peptide (NT-proBNP) or BNP preoperatively to improve risk prediction in 3 groups (strong recommendation; moderate-quality evidence):

- Patients ages 65 and older
- Patients ages 45 to 64 with significant cardiovascular disease
- Patients with an RCRI score of 1 or more.

This differs from the American guidelines, which did not recommend measuring preoperative biomarkers but did acknowledge that they may provide incremental value. The American College of Cardiology/American Heart Association authors felt that there were no data to suggest that targeting these biomarkers for treatment and intervention would reduce postoperative risk. The European guidelines did

TABLE 1

### Minimum duration for surgical delay after percutaneous coronary intervention

Type of coronary intervention	Delay for nonurgent surgery
Angioplasty <u>without</u> stenting	14 days <sup>2</sup>
<u>Bare-metal</u> stent	30 days <sup>16</sup>
<u>Drug-eluting</u> stent	Optimal: 6 months <sup>16</sup> 3–6 months if benefits of surgery <u>outweigh</u> risks of stent thrombosis <sup>16</sup>

From references 2 and 16.

not recommend routinely using biomarkers, but stated that they may be considered in high-risk patients (who have a functional capacity  $\leq$  4 metabolic equivalents or an RCRI score  $> 1$  undergoing vascular surgery, or  $> 2$  undergoing nonvascular surgery).

**Stress testing deemphasized.** The Canadian guidelines recommended biomarker testing rather than noninvasive tests to enhance risk assessment based on cost, potential delays in surgery, and absence of evidence of an overall absolute net improvement in risk reclassification. This contrasts with the American and European guidelines and algorithms, which recommended pharmacologic stress testing in patients at elevated risk with poor functional capacity undergoing intermediate- to high-risk surgery if the results would change how they are managed.

**Postoperative monitoring.** The Canadian guidelines recommended that if patients have an NT-proBNP level higher than 300 mg/L or a BNP level higher than 92 mg/L, they should receive postoperative monitoring with electrocardiography in the postanesthesia care unit and daily troponin measurements for 48 to 72 hours. The American guidelines recommended postoperative electrocardiography and troponin measurement only for patients suspected of having myocardial ischemia, and the European guidelines said postoperative biomarkers may be considered in patients at high risk.

#### Physician judgment needed

While guidelines and risk calculators are potentially helpful in risk assessment, the lack of consensus and the conflicting recommen-

dations force the physician to weigh the evidence and make individual decisions based on his or her interpretation of the data.

Until there are studies directly comparing the various risk calculators, physicians will most likely use the RCRI, which is simple and has been externally validated, in conjunction with the American guidelines.

At this time, it is unclear how biomarkers should be used—preoperatively, postoperatively, or both—because there are no studies demonstrating that management strategies based on the results lead to better outcomes. We do not believe that biomarker testing will be accepted in lieu of stress testing by our surgery, anesthesiology, or cardiology colleagues, but going forward, it will probably be used more frequently postoperatively, particularly in patients at moderate to high risk.

#### WHAT IS THE APPROPRIATE TIMING FOR SURGERY AFTER PCI?

A 2014 American College of Cardiology/American Heart Association guideline recommended delaying noncardiac surgery for 1 month after percutaneous coronary intervention (PCI) with bare-metal stents and 1 year after PCI with drug-eluting stents.<sup>15</sup> The guideline suggested that surgery may be performed 6 months after drug-eluting stent placement if the risks of delaying surgery outweigh the risk of thrombosis.<sup>15</sup>

The primary rationale behind these timeframes was to provide dual antiplatelet therapy for a minimally acceptable duration before temporary interruption for a procedure. These recommendations were influenced largely by

New Canadian guidelines differ from American and European ones on perioperative risk assessment



observational studies of first-generation devices, which are no longer used. Studies of newer-generation stents have suggested that the risk of stent thrombosis reaches a plateau considerably earlier than 6 to 12 months after PCI.

### 2016 Revised guideline on dual antiplatelet therapy

In 2016, the American College of Cardiology and American Heart Association revised their recommendations for the timing of noncardiac surgery after PCI in view of the new data.<sup>3</sup> They continue to recommend waiting 30 days to perform surgery after PCI with bare-metal stents but now consider 6 months after drug-eluting stent placement as an optimal delay duration (Table 1).<sup>2,16</sup> Noncardiac surgery may be performed 3 to 6 months after drug-eluting stent placement if the benefits of surgery are considered greater than the risks of stent thrombosis.

Although not separately delineated in the recommendations, risk factors for stent thrombosis that should influence the decision include smoking, multivessel coronary artery disease, and suboptimally controlled diabetes mellitus or hyperlipidemia.<sup>17</sup> The presence of such stent thrombosis risk factors should be factored into the decision about proceeding with surgery within 3 to 6 months after drug-eluting stent placement.

### Holcomb et al: Higher postoperative risk after PCI for myocardial infarction

Another important consideration is the indication for which PCI was performed. In a recent study, Holcomb et al<sup>16</sup> found an association between postoperative major adverse cardiac events and PCI for myocardial infarction (MI) that was independent of stent type.

Compared with patients who underwent PCI not associated with acute coronary syndrome, the odds ratios and 95% confidence intervals (CIs) for major adverse cardiac events in those who underwent PCI for MI were:

- 5.25 (4.08–6.75) in the first 3 months
- 2.45 (1.80–3.35) in months 3 to 6
- 2.50 (1.90–3.28) in months 6 to 12.

In absolute terms, patients with stenting performed for an MI had an incidence of major adverse cardiac events of:

- 22.2% in the first 3 months

- 9.4% in months 3 to 6
- 5.8% in months 6 to 12
- 4.4% in months 12 to 24.

The perioperative risks were reduced after 12 months but still remained greater in patients whose PCI was performed for MI rather than another indication.<sup>16</sup>

The authors of this study suggested delaying noncardiac surgery for up to 6 months after PCI for MI, regardless of stent type.<sup>16</sup>

### A careful, individualized approach

Optimal timing of noncardiac surgery PCI requires a careful, individualized approach and should always be coordinated with the patient's cardiologist, surgeon, and anesthesiologist.<sup>3,15</sup> For most patients, surgery should be delayed for 30 days after bare-metal stent placement and 6 months after drug-eluting stent placement.<sup>3</sup> However, for those with greater surgical need and less thrombotic risk, noncardiac surgery can be considered 3 to 6 months after drug-eluting stent placement.<sup>3</sup>

Additional discussion of the prolonged increased risk of postoperative major adverse cardiac events is warranted in patients whose PCI was performed for MI, in whom delaying noncardiac surgery for up to 6 months (irrespective of stent type) should be considered.<sup>16</sup>

### CAN WE USE STATINS TO REDUCE PERIOPERATIVE RISK?

Current recommendations from the American College of Cardiology/American Heart Association support continuing statins in the perioperative period, but the evidence supporting starting statins in this period has yet to be fully determined. In 2013, a Cochrane review<sup>18</sup> found insufficient evidence to conclude that statins reduced perioperative adverse cardiac events, though several large studies were excluded due to controversial methods and data.

In contrast, the Vascular Events in Noncardiac Surgery Patients Cohort Evaluation (VISION) study,<sup>4</sup> a multicenter, prospective, cohort-matched study of approximately 7,200 patients, found a lower risk of a composite primary outcome of all-cause mortality, myocardial injury after noncardiac surgery, or stroke at 30 days for patients exposed to statin therapy (relative risk [RR] 0.83, 95% CI 0.73–0.95,  $P = .007$ ).<sup>4</sup>

**New guidelines:  
shorter delay  
of surgery  
after PCI**

Continuing  
statins  
perioperatively  
seems  
beneficial;  
starting them  
needs to  
be studied

### London et al retrospective study: 30-day mortality rate is lower with statins

In 2017, London et al<sup>5</sup> published the results of a very large retrospective, observational cohort study of approximately 96,000 elective or emergency surgery patients in Department of Veterans Affairs hospitals. The patients were propensity-matched and evaluated for exposure to statins on the day of or the day after surgery, for a total of approximately 48,000 pairs.

The primary outcome was death at 30 days, and statin exposure was associated with a significant reduction (RR 0.82; 95% CI 0.75–0.89;  $P < .001$ ). Significant risk reductions were demonstrated in nearly all secondary end points as well, except for stroke or coma and thrombosis (pulmonary embolism, deep vein thrombosis, or graft failure). Overall, the number needed to treat to prevent any complication was 67. Statin therapy did not show significant harm, though on subgroup analysis, those who received high-intensity statin therapy had a slightly higher risk of renal injury (odds ratio 1.18, 95% CI 1.02–1.37,  $P = .03$ ). Also on subgroup analysis, after propensity matching, patients on long-term moderate- or high-intensity statin therapy for 6 to 12 months before surgery had a small risk reduction for many of the outcomes, including death.

The authors also noted that only 62% of the patients who were prescribed statins as outpatients received them in the hospital, which suggests that improvement is necessary in educating perioperative physicians about the benefits and widespread support for continuing statins perioperatively.<sup>5</sup>

### LOAD trial: No benefit from starting statins

Both London et al<sup>5</sup> and the VISION investigators<sup>4</sup> called for a large randomized controlled trial of perioperative statin initiation. The Lowering the Risk of Operative Complications Using Atorvastatin Loading Dose (LOAD) trial attempted to answer this call.<sup>6</sup>

This trial randomized 648 statin-naïve Brazilian patients at high risk of perioperative cardiac events to receive either atorvastatin or placebo before surgery and then continuously for another 7 days. The primary outcomes were the rates of death, nonfatal myocardial injury after noncardiac surgery, and cerebrovascular accident at 30 days.<sup>6</sup>

The investigators found no significant difference in outcomes between the two groups and estimated that the sample size would need to be approximately 7,000 patients to demonstrate a significant benefit. Nonetheless, this trial established that a prospective perioperative statin trial is feasible.

### When to continue or start statins

Although we cannot recommend starting statins for all perioperative patients, perioperative statins clearly can carry significant benefit and should be continued in all patients who have been taking them. It is also likely beneficial to initiate statins in those patients who would otherwise warrant therapy based on the American College of Cardiology/American Heart Association Pooled Cohort Equations Risk calculator.<sup>19</sup>

### ■ HOW SHOULD WE MANAGE SLEEP APNEA RISK PERIOPERATIVELY?

From 20% to 30% of US men and 10% to 15% of US women have obstructive sleep apnea, and many are undiagnosed. Obstructive sleep apnea increases the risk of perioperative respiratory failure, unplanned reintubation, unplanned transfer to the intensive care unit, and death.<sup>20</sup> Sentinel events (unexpected respiratory arrest after surgery on general surgical wards) have prompted the development of guidelines that aim to identify patients with previously undiagnosed obstructive sleep apnea before surgery and to develop approaches to reduce perioperative morbidity and mortality.

#### Kaw et al:

#### Beware obesity hypoventilation syndrome

A 2016 study suggested that patients with obstructive sleep apnea and obesity hypoventilation syndrome may be at particularly high risk of perioperative complications.<sup>21</sup>

Kaw et al<sup>21</sup> queried a database of patients with obstructive sleep apnea undergoing elective noncardiac surgery at Cleveland Clinic. All patients ( $N = 519$ ) had obstructive sleep apnea confirmed by polysomnography, and a body mass index greater than 30 kg/m<sup>2</sup>. The authors considered a patient to have obesity hypoventilation syndrome ( $n = 194$ ) if he or she also had hypercapnia ( $Paco_2 \geq 45$  mm Hg) on at least 2 occasions before or after surgery.

In an adjusted analysis, the odds ratios and 95% CIs for adverse outcomes in patients with obesity hypoventilation syndrome were:

- 10.9 (3.7–32.3) for respiratory failure
- 5.4 (1.9–15.7) for heart failure
- 10.9 (3.7–32.3) for intensive care unit transfer.

The absolute increases in risk in the presence of obesity hypoventilation syndrome were:

- 19% (21% vs 2%) for respiratory failure
- 8% (8% vs 0) for heart failure
- 15% (21% vs 6%) for intensive care unit transfer.

There was no difference in rates of perioperative mortality.<sup>21</sup>

The authors proposed an algorithm to identify patients with possible obesity hypoventilation syndrome before surgery that included prior sleep study results, STOP-BANG score (Table 2),<sup>22</sup> and serum bicarbonate level.

Important limitations of the study were that most patients with obesity hypoventilation syndrome were undiagnosed at the time of surgery. Still, the study does offer a tool to potentially identify patients at high risk for perioperative morbidity due to obesity hypoventilation syndrome. Clinicians could then choose to cancel nonessential surgery, propose a lower-risk alternative procedure, or maximize the use of strategies known to reduce perioperative risk for patients with obstructive sleep apnea in general.

### Two guidelines on obstructive sleep apnea

Two professional societies have issued guidelines aiming to improve detection of previously undiagnosed obstructive sleep apnea and perioperative outcomes in patients known to have it or suspected of having it:

- The American Society of Anesthesiologists in 2014<sup>23</sup>
- The Society of Anesthesia and Sleep Medicine in 2016.<sup>7</sup>

Both guidelines recommend that each institution develop a local protocol to screen patients for possible obstructive sleep apnea before elective surgery. The American Society of Anesthesiologists does not recommend any particular tool, but does recommend taking a history and performing a focused examination that includes evaluation of the airway, nasopharyngeal characteristics, neck circumference, and tonsil and tongue size. The So-

TABLE 2

### STOP-BANG score to estimate the risk of obstructive sleep apnea

**Snoring:** Do you snore loudly (loud enough to be heard through closed doors)?

**Tired:** Do you often feel tired, fatigued, or sleepy during daytime?

**Observed:** Has anyone observed you stop breathing during your sleep?

**Blood Pressure:** Do you have or are you being treated for high blood pressure?

**BMI** more than 35 kg/m<sup>2</sup>?

**Age** older than 50?

**Neck circumference** > 40 cm (16 in)?

**Gender** male?

• Low risk of obstructive sleep apnea: Yes to 0–2 questions

• High risk: Yes to 3 or more questions

From Chung F, Yegneswaran B, Liao P, et al. STOP questionnaire: a tool to screen patients for obstructive sleep apnea. *Anesthesiology* 2008; 108:812–821, [anesthesiology.pubs.asahq.org/journal.aspx](http://anesthesiology.pubs.asahq.org/journal.aspx).

ciety of Anesthesia and Sleep Medicine recommends using a validated tool such as the STOP-BANG score to estimate the risk of obstructive sleep apnea.

If this screening suggests that a patient has obstructive sleep apnea, should surgery be delayed until a formal sleep study can be done? Or should the patient be treated empirically as if he or she has obstructive sleep apnea? Both professional societies recommend shared decision-making with the patient in this situation, with the Society of Anesthesia and Sleep Medicine recommending additional cardiopulmonary evaluation for patients with hypoventilation, severe pulmonary hypertension, or resting hypoxemia.

Both recommend using continuous positive airway pressure (CPAP) after surgery in patients with known obstructive sleep apnea, although there is not enough evidence to determine if empiric CPAP for screening-positive patients (without polysomnography-diagnosed obstructive sleep apnea) is beneficial. The Society of Anesthesia and Sleep Medicine advises that it is safe to proceed to surgery if obstructive sleep apnea is suspected as long

**20%–30% of US men and 10%–15% of US women have obstructive sleep apnea, and many are undiagnosed**

as monitoring and risk-reduction strategies are implemented after surgery to reduce complication rates.

During surgery, the American Society of Anesthesiologists advises peripheral nerve blocks when appropriate, general anesthesia with a secure airway rather than deep sedation, capnography when using moderate sedation, awake extubation, and full reversal of neuromuscular blockade before extubation. After surgery, they recommend reducing opioid use, minimizing postoperative sedatives, supplemental oxygen, and continuous pulse oximetry. The Society of Anesthesia and Sleep Medicine guideline addresses preoperative assessment and therefore makes no recommendations regarding postoperative care.

In conclusion, use of pertinent findings from the history and physical examination and a validated obstructive sleep apnea screening tool such as STOP-BANG before surgery are recommended, with joint decision-making as to proceeding with surgery with empiric CPAP vs a formal sleep study for patients who screen as high risk. The Society of Anesthesia and Sleep Medicine recommends further cardiopulmonary evaluation if there is evidence of hypoventilation, hypoxemia, or pulmonary hypertension in addition to likely obstructive sleep apnea.

#### ■ WHICH ATRIAL FIBRILLATION PATIENTS NEED BRIDGING ANTICOAGULATION?

When patients receiving anticoagulation need surgery, we need to carefully assess the risks of thromboembolism without anticoagulation vs bleeding with anticoagulation.

Historically, we tended to worry more about thromboembolism<sup>24</sup>; however, recent studies have revealed a significant risk of bleeding when long-term anticoagulant therapy is bridged (ie, interrupted and replaced with a shorter-acting agent in the perioperative period), with minimal to no decrease in thromboembolic events.<sup>25-27</sup>

#### American College of Cardiology guideline

In 2017, the American College of Cardiology<sup>8</sup> published a guideline on periprocedural management of anticoagulation in patients with nonvalvular atrial fibrillation. The guideline includes a series of decision algorithms on

whether and when to interrupt anticoagulation, whether and how to provide bridging anticoagulation, and how to restart postprocedural anticoagulation.

When deciding whether to interrupt anticoagulation, we need to consider the risk of bleeding posed both by patient-specific factors and by the type of surgery. Bridging anticoagulation is not indicated when direct oral anticoagulants (eg, dabigatran, apixaban, edoxaban, rivaroxaban) are interrupted for procedures.

Unlike an earlier guideline statement by the American College of Chest Physicians,<sup>24</sup> this consensus statement emphasizes using the CHA<sub>2</sub>DS<sub>2</sub>-VASc score as a predictor of thromboembolic events rather than the CHADS<sub>2</sub> score.

Table 3 summarizes the key points in the guidance statement about which patients should receive periprocedural bridging anticoagulation.

As evidence continues to evolve in this complicated area of perioperative medicine, it will remain important to continue to create patient management plans that take individual patient and procedural risks into account.

#### ■ IS FRAILTY SCREENING BENEFICIAL BEFORE NONCARDIAC SURGERY?

Frailty, defined as a composite score of a patient's age and comorbidities, has great potential to become an obligatory factor in perioperative risk assessment. However, it remains difficult to incorporate frailty scoring into clinical practice due to variations among scoring systems,<sup>28</sup> uncertain outcome data, and the imprecise role of socioeconomic factors. In particular, the effect of frailty on perioperative mortality over longer periods of time is uncertain.

#### Mclsaac et al: Higher risk in frail patients

Mclsaac and colleagues at the University of Ottawa used a frailty scoring system developed at Johns Hopkins University to evaluate the effect of frailty on all-cause postoperative mortality in approximately 202,000 patients over a 10-year period.<sup>9</sup> Although this scoring system is proprietary, it is based on factors such as malnutrition, dementia, impaired vision, decubitus ulcers, urinary incontinence, weight loss, poverty, barriers to access of care, difficulty in walking, and falls.

Treat possible obstructive sleep apnea empirically or pursue formal sleep studies?



TABLE 3

### American College of Cardiology recommendations: Perioperative anticoagulation in patients with atrial fibrillation

Thromboembolic risk category	Bleeding risk category	Recommendation
<b>Low</b> ( $\leq 5\%$ /year, CHA <sub>2</sub> DS <sub>2</sub> -VASC $\leq 4$ ) <sup>a</sup>	All levels of bleeding	Interrupt vitamin K antagonists <b>without</b> bridging
<b>Moderate</b> ( $5\%–10\%$ /year, CHA <sub>2</sub> DS <sub>2</sub> -VASC <b>5 or 6</b> )	High procedural bleeding risk	Interrupt vitamin K antagonists <b>without</b> bridging
	No significant bleeding risk <i>without</i> history of stroke, transient ischemic attack, or systemic embolism	Interrupt vitamin K antagonists <b>without</b> bridging
	<b>No significant bleeding risk with history</b> of stroke, transient ischemic attack, or systemic embolism	<b>Consider bridging</b>
<b>High</b> ( $> 10\%$ /year, CHA <sub>2</sub> DS <sub>2</sub> -VASC $\geq 7$ )	All levels of <b>bleeding risk</b>	Should generally be considered for <b>bridging</b>
	<b>High</b> bleeding risk	Apply clinical <b>judgment</b>

<sup>a</sup>CHA<sub>2</sub>DS<sub>2</sub>-VASC = 1 point for congestive heart failure, hypertension, age 65 to 75, diabetes, vascular disease, or female sex; 2 points for history of either stroke or transient ischemic attack or thromboembolism, and/or age  $\geq 75$ .

Based on information in reference 25.

After adjusting for the procedure risk, patient age, sex, and neighborhood income quintile, the **1-year mortality risk** was significantly higher in the **frail group** (absolute risk **13.6%** vs **4.8%**; adjusted hazard ratio 2.23; 95% CI 2.08–2.40). The risk of death in the **first 3 days** was much higher in **frail** than in nonfrail patients (**hazard** ratio **35.58**; 95% CI 29.78–40.1), but the hazard ratio decreased to approximately **2.4** by day 90.

The authors emphasize that the elevated risk for frail patients warrants particular perioperative planning, though it is not yet clear what frailty-specific interventions should be performed. **Further study** is needed into the benefit of “**prehabilitation**” (ie, exercise training to “build up” a patient before surgery) for perioperative risk reduction.

#### Hall et al: Better care for frail patients

Hall et al<sup>10</sup> instituted a quality improvement initiative for perioperative care of patients at the Omaha Veterans Affairs Hospital. Frail patients were identified using the Risk Analysis Index, a 14-question screening tool previously

developed and validated over several years using Veterans Administration databases.<sup>29</sup> Questions in the Risk Analysis Index cover living situation, any diagnosis of cancer, ability to perform activities of daily living, and others.

To maximize compliance, a Risk Analysis Index score was required to schedule a surgery. Patients with high scores underwent further review by a designated team of physicians who initiated informal and formal consultations with anesthesiologists, critical care physicians, surgeons, and palliative care providers, with the goals of minimizing risk, clarifying patient goals or resuscitation wishes, and developing **comprehensive perioperative planning**.<sup>10</sup>

Approximately **9,100** patients were included in the cohort. The authors demonstrated a **significant improvement in mortality** for **frail** patients at 30, 180, and 365 days, but noted an improvement in **postoperative mortality** for the **nonfrail** patients as well, perhaps due to increased focus on geriatric patient care. In particular, the **mortality** rate at **365 days** dropped from **34.5%** to **11.7%** for **frail** patients who underwent this intervention.

**Direct oral anticoagulants do not require bridging**



While this quality improvement initiative was unable to examine how surgical rates changed in frail patients, it is highly likely that very high-risk patients opted out of surgery or had their surgical plan change, though the authors point out that the overall surgical volume at the institution did not change significantly. As well, it remains unclear which particular interventions may have had the most effect in improving survival, as the perioperative plans were individualized and continually adjusted throughout the study period.

Nonetheless, this article highlights how higher vigilance, individualized planning and appreciation of the high risks of frail patients is associated with improved patient survival postoperatively. Although frailty screening is still in its early stages and further work is needed, it is likely that performing frailty screening in elderly patients and utilizing interdisciplinary collaboration for comprehensive management of frail patients can improve their postoperative course.

## REFERENCES

1. Duceppe E, Parlow J, MacDonald P, et al. Canadian Cardiovascular Society guidelines on perioperative cardiac risk assessment and management for patients who undergo noncardiac surgery. *Can J Cardiol* 2017; 33:17–32.
2. Fleisher LA, Fleischmann KE, Auerbach AD, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. *J Am Coll Cardiol* 2014; 64:2373–2405.
3. Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease. *Circulation* 2016; 134:e123–e155.
4. Berwanger O, Le Manach Y, Suzumura EA, et al. Association between pre-operative statin use and major cardiovascular complications among patients undergoing non-cardiac surgery: the VISION study. *Eur Heart J* 2016; 37:177–185.
5. London MJ, Schwartz GG, Hur K, Henderson WG. Association of perioperative statin use with mortality and morbidity after major noncardiac surgery. *JAMA Intern Med* 2017; 177:231–242.
6. Berwanger O, de Barros E Silva PG, Barbosa RR, et al. Atorvastatin for high-risk statin-naïve patients undergoing noncardiac surgery: the Lowering the Risk of Operative Complications Using Atorvastatin Loading Dose (LOAD) randomized trial. *Am Heart J* 2017; 184:88–96.
7. Chung F, Memtsoudis SG, Ramachandran SK, et al. Society of Anesthesia and Sleep Medicine guidelines on preoperative screening and assessment of adult patients with obstructive sleep apnea. *Anesth Analg* 2016; 123:452–473.
8. Doherty JU, Gluckman TJ, Hucker W, et al. 2017 ACC expert consensus decision pathway for periprocedural management of anticoagulation in patients with nonvalvular atrial fibrillation: a report of the American College of Cardiology Clinical Expert Consensus Document Task Force. *J Am Coll Cardiol* 2017; 69:871–898.
9. McIsaac DI, Bryson GL, van Walraven C. Association of frailty and 1-year postoperative mortality following major elective noncardiac surgery: a population-based cohort study. *JAMA Surg* 2016; 151:538–545.
10. Hall DE, Arya S, Schmid KK, et al. Association of a frailty screening initiative with postoperative survival at 30, 180, and 365 days. *JAMA Surg* 2017; 152:233–240.
11. Kristensen SD, Knuuti J, Saraste A, et al. 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). *Eur Heart J* 2014; 35:2383–2431.
12. Lee TH, Marcantonio ER, Mangione CM, et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. *Circulation* 1999; 100:1043–1049.
13. Billmoria KY, Liu Y, Paruch JL, Zhou L, Kniecik TE, Ko CY, Cohen ME. Development and evaluation of the universal ACS NSQIP surgical risk calculator: a decision aid and informed consent tool for patients and surgeons. *J Am Coll Surg* 2013; 217:833–842.
14. Gupta PK, Gupta H, Sundaram A, et al. Development and validation of a risk calculator for prediction of cardiac risk after surgery. *Circulation* 2011; 124:381–387.
15. Fleisher LA, Fleischmann KE, Auerbach AD, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 2014; 64:e77–e137.
16. Holcomb CN, Hollis RH, Graham LA, et al. Association of coronary stent indication with postoperative outcomes following noncardiac surgery. *JAMA Surg* 2016; 151:462–469.
17. Lemesle G, Tricot O, Meurice T, et al. Incident myocardial infarction and very late stent thrombosis in outpatients with stable coronary artery disease. *J Am Coll Cardiol* 2017; 69:2149–2156.
18. Sanders RD, Nicholson A, Lewis SR, Smith AF, Alderson P. Perioperative statin therapy for improving outcomes during and after noncardiac vascular surgery. *Cochrane Database Syst Rev* 2013; 7:CD009971.
19. Goff DC, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 2014; 63:2935–2959.
20. Kaw R, Pasupuleti V, Walker E, et al. Postoperative complications in patients with obstructive sleep apnea. *Chest* 2012; 141:436–441.
21. Kaw R, Bhateja P, Mar HP, et al. Postoperative complications in patients with unrecognized obesity hypoventilation syndrome undergoing elective noncardiac surgery. *Chest* 2016; 149:84–91.
22. Chung F, Yegneswaran B, Liao P, et al. STOP questionnaire: a tool to screen patients for obstructive sleep apnea. *Anesthesiology* 2008; 108:812–821.
23. Gross JB, Apfelbaum JL, Caplan RA, et al. Practice guidelines for the perioperative management of patients with obstructive sleep apnea: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Management of Patients with Obstructive Sleep Apnea. *Anesthesiology* 2014; 120:268–286.
24. Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 2012; 141(2 suppl):e326S–e350S.
25. Siegal D, Yudin J, Kaatz S, Douketis JD, Lim W, Spyropoulos AC. Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. *Circulation* 2012; 126:1630–1639.
26. Clark NP, Witt DM, Davies LE, et al. Bleeding, recurrent venous thromboembolism, and mortality risks during warfarin interruption for invasive procedures. *JAMA Intern Med* 2015; 175:1163–1168.
27. Douketis JD, Spyropoulos AC, Kaatz S, et al. Perioperative bridging anticoagulation in patients with atrial fibrillation. *N Engl J Med* 2015; 373:823–833.
28. Theou O, Brothers TD, Mitnitski A, Rockwood K. Operationalization of frailty using eight commonly used scales and comparison of their ability to predict all-cause mortality. *J Am Geriatr Soc* 2013; 61:1537–1551.
29. Hall DE, Arya S, Schmid KK, et al. Development and initial validation of the risk analysis index for measuring frailty in surgical populations. *JAMA Surg* 2017; 152:175–182.

ADDRESS: Ryan Munyon, MD, Penn State Hershey Medical Center, Mail Code H034, 500 University Drive, Hershey, PA 17033; [rmunyon@pennstatehealth.psu.edu](mailto:rmunyon@pennstatehealth.psu.edu)